These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 19447443)

  • 21. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate.
    Ferreira U; Matheus WE; Nardi Pedro R; Levi D'Ancona CA; Reis LO; Stopiglia RM; Denardi F; Rodrigues Netto N; de Cássio Zequi S; da Fonseca FP; Lopes A; Cardoso Guimarães G; de Carvalho Fernandes R; Cardenuto Perez MD
    Urol Int; 2007; 79(3):200-3. PubMed ID: 17940350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
    Wright JL; Black PC; Brown GA; Porter MP; Kamat AM; Dinney CP; Lin DW
    J Urol; 2007 Dec; 178(6):2302-6; discussion 2307. PubMed ID: 17936803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study.
    Osawa T; Abe T; Shinohara N; Harabayashi T; Sazawa A; Kubota K; Matsuno Y; Shibata T; Shinno Y; Kamota S; Minami K; Sakashita S; Kumagai A; Mori T; Nonomura K
    Int J Urol; 2009 Mar; 16(3):274-8; discussion 278. PubMed ID: 19087211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
    Okajima E; Fujimoto H; Mizutani Y; Kikuchi E; Koga H; Hinotsu S; Shinohara N; Miki T;
    Int J Urol; 2010 Nov; 17(11):905-12. PubMed ID: 20969637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.
    Esrig D; Freeman JA; Elmajian DA; Stein JP; Chen SC; Groshen S; Simoneau A; Skinner EC; Lieskovsky G; Boyd SD; Cote RJ; Skinner DG
    J Urol; 1996 Sep; 156(3):1071-6. PubMed ID: 8709310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
    Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
    BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
    Boorjian SA; Kim SP; Tollefson MK; Carrasco A; Cheville JC; Thompson RH; Thapa P; Frank I
    J Urol; 2013 Jul; 190(1):55-60. PubMed ID: 23313198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.